Publications by authors named "Thomas Stinchcombe"

Claim this Profile
P
Patient and oncologist preferences for ALK+ advanced non-small cell lung cancer tyrosine kinase inhibitor treatments: a discrete choice experiment in the United States.
Hannah Le, Josh Coulter, Ken Culver, Joseph C Cappelleri, Nada Rifi, Thomas E Stinchcombe

Lung Cancer· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Given TKIs With High CNS Penetrance, Systemic Therapy Should Be Administered Before Radiation Therapy for CNS Metastases.
Laura Alder, Sandip P Patel, Thomas E Stinchcombe

J Thorac Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LiveWell: Pilot Feasibility Trial of an Adapted Dialectical Behavioral Therapy Skills Training Protocol in Patients With Metastatic Non-Small Cell Lung Cancer.
Kelly A Hyland, Andrada D Neacsiu, Hannah M Fisher, Colleen M Cowperthwait, Natalie Chou, Thomas E Stinchcombe

Psychooncology· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non-small cell lung cancer.
Hirva Mamdani, Ryan D Gentzler, Lin Gu, Alberto A Chiappori, Frank D Weinberg, Thomas E Stinchcombe

Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The extent of lymph node dissection is not associated with disease-free survival following lobar or sublobar resection: Results from Cancer and Leukemia Group B 140503 (Alliance).
Nasser Altorki, Bryce Damman, Xiaofei Wang, Moishe Liberman, Dennis Wigle, Thomas E Stinchcombe

J Thorac Cardiovasc Surg· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Milademetan in Advanced Solid Tumors with MDM2 Amplification and Wild-type TP53: Preclinical and Phase II Clinical Trial Results.
Ecaterina E Dumbrava, Thomas E Stinchcombe, Mrinal Gounder, Gregory M Cote, Glenn J Hanna

Clin Cancer Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-Institution Analysis of Tarlatamab for the Treatment of -Mutant Transformed Small Cell Lung Cancer.
Alissa J Cooper, Benjamin Herzberg, Mitchell Parma, Kaiwen Wang, Laura Alder, Thomas E Stinchcombe

JCO Precis Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Osimertinib: A Step Ahead or Just a Step?
Suresh S Ramalingam, Thomas E Stinchcombe

J Clin Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early-Phase Trials in .
Thomas E Stinchcombe, Gini F Fleming, Charles Craddock, Andrew H Ko, Eileen M O'Reilly

J Clin Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Convolutional Neural Networks for Segmentation of Pleural Mesothelioma: Analysis of Probability Map Thresholds (CALGB 30901, Alliance).
Mena Shenouda, Eyjólfur Gudmundsson, Feng Li, Christopher M Straus, Hedy L Kindler, Thomas Stinchcombe

J Imaging Inform Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to: Lobectomy, segmentectomy, or wedge resection for peripheral clinical T1aN0 non-small cell lung cancer: A post hoc analysis of CALGB 140503 (Alliance)" [The Journal of Thoracic and Cardiovascular Surgery Volume 167, Issue 1, January 2024, Pages 338-347.e1].
Nasser Altorki, Xiaofei Wang, Bryce Damman, Jennifer Mentlick, Rodney Landreneau, Thomas E Stinchcombe

J Thorac Cardiovasc Surg· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Uncertain Prognostic Impact of Visceral Pleural Invasion-Reply.
Nasser Altorki, Xiaofei Wang, Thomas E Stinchcombe

JAMA Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development, Review, and Activation of Thoracic Oncology Investigator-Initiated Trials.
David E Gerber, Claire R Wynters, Tanushree Prasad, Ronny K Schnel, Song Zhang, Thomas E Stinchcombe

Clin Cancer Res· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial.
Alicia F C Okines, Giuseppe Curigliano, Nobumasa Mizuno, Do-Youn Oh, Andree Rorive, Thomas E Stinchcombe

Nat Med· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Temporal Trends in the Utilization and Survival Outcomes of Lobar, Segmental, and Wedge Resection for Early-Stage NSCLC, 2004 to 2020.
Eden Z Deng, Xiaofei Wang, Jianrong Zhang, Thomas E Stinchcombe, Chi-Fu Jeffrey Yang

JTO Clin Res Rep· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis.
Cameron Wood, Liliana Lyniv, James M Isaacs, Jacob M Kaufman, Eziafa I Oduah, Thomas Stinchcombe

J Immunother Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inclusion of Surgery in Multimodality Treatment is Predictive of Better Survival in Stage IIIA Non-small Cell Lung Cancer: An Inverse Probability Treatment-Weighting Analysis.
Feitong Lei, Janeesh Sekkath-Veedu, Bin Huang, Quan Chen, Mansi Shah-Jadeja, Thomas E Stinchcombe

Clin Lung Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life outcomes in patients participating in the CALGB 30610 trial (CALGB 70702): Alliance.
Apar K Ganti, Briant Fruth, Andreas Rimner, Saiama Waqar, Michael D Mix, Thomas E Stinchcombe

Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial.
Jeffrey M Clarke, George R Simon, Hirva Mamdani, Lin Gu, James E Herndon, Thomas E Stinchcombe

Nat Commun· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combining Response and Toxicity Data to Implement Project Optimus.
Robert G Maki, Thomas E Stinchcombe, Gary K Schwartz, Gini F Fleming, Alexia E Iasonos

J Clin Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lung Cancer Screening and Early Detection Terminology: Time to Sing From the Same Song Sheet.
Betty C Tong, Thomas E Stinchcombe

J Thorac Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidermal growth factor receptor exon 20 insertion mutations: are we getting closer to solving the puzzle?
Thomas E Stinchcombe

Transl Lung Cancer Res· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Factors in Limited-Stage Small Cell Lung Cancer: A Secondary Analysis of CALGB 30610-RTOG 0538.
Michael K Farris, Michael D Mix, Xiaofei Wang, Brandy Jaszewski, Nathan Foster, Thomas E Stinchcombe

JAMA Netw Open· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II Nonrandomized Controlled Trial.
Helen J Ross, David Kozono, Xiaofei F Wang, James John Urbanic, Terence M Williams, Thomas E Stinchcombe

JAMA Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recurrence of Non-Small Cell Lung Cancer With Visceral Pleural Invasion: A Secondary Analysis of a Randomized Clinical Trial.
Nasser Altorki, Xiaofei Wang, Bryce Damman, David R Jones, Dennis Wigle, Thomas E Stinchcombe

JAMA Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis